Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Melanoma Negative for bRAF”

4 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 4 of 4 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT06784648
What this trial is testing

Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma

Who this might be right for
Melanoma MetastaticMelanoma of SkinMelanoma BRAF V600E/K Mutated+7 more
BioInvent International AB 35
Early research (Phase 1)Study completedNCT01351103
What this trial is testing

LGK974 in Patients With Malignancies Dependent on Wnt Ligands

Who this might be right for
Pancreatic CancerBRAF Mutant Colorectal CancerMelanoma+5 more
Novartis Pharmaceuticals 185
Early research (Phase 1)Study completedNCT01138085
What this trial is testing

Safety, Pharmacokinetics (PK) of AKT and MEK Combination

Who this might be right for
Cancer
GlaxoSmithKline 240
Post-approval studies (Phase 4)Study completedNCT01794793
What this trial is testing

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

Who this might be right for
Cushing's DiseaseAcromegalyNeuroendocrine Tumors+6 more
RECORDATI GROUP 337